O. Delattre

This study compares genomic and phenotypic stability of pediatric Ewing sarcoma cell lines to adult carcinoma cell lines over 12 months of culture.

This paper presents a microfluidics platform for drug screening on cancer spheroids, reducing cell requirements and enabling sequential drug exposure.

This study identifies KCNN1 as a target of EWS-FLI1 and EWS-ERG fusion proteins in Ewing Sarcoma, showing its role in cell proliferation and potential as a therapeutic target.

This study evaluates lorlatinib, an ALK inhibitor, in combination with chemotherapy or idasanutlin in preclinical neuroblastoma models, finding synergy in models with high ALK expression.

This study identifies VGLL2-NCOA2 as an oncogene driving pediatric sarcomagenesis by reactivating developmental programs, with ARF6 overexpression as a potential therapeutic target.

This study shows that neuroblastoma cells can switch between noradrenergic and mesenchymal identities through epigenetic reprogramming, influenced by both intrinsic factors and the microenvironment.

This study identifies retroelement RNAs in Ewing Sarcoma exosomes that induce inflammation and immunosuppression in recipient cells.

This study shows how a dominant oncogene and regulatory germline variants together influence tumor growth, survival, and drug response in Ewing sarcoma.

This study identifies transcriptional programs driving intratumoral heterogeneity in Ewing sarcoma using single-cell RNA-sequencing and chromatin analysis.

This study establishes a zebrafish model of CIC-DUX4 sarcoma, showing that CIC-DUX4 drives tumor development and that Etv4 is critical for its oncogenic effects.